CA3286798A1 - Markers of endometrial cancer - Google Patents

Markers of endometrial cancer

Info

Publication number
CA3286798A1
CA3286798A1 CA3286798A CA3286798A CA3286798A1 CA 3286798 A1 CA3286798 A1 CA 3286798A1 CA 3286798 A CA3286798 A CA 3286798A CA 3286798 A CA3286798 A CA 3286798A CA 3286798 A1 CA3286798 A1 CA 3286798A1
Authority
CA
Canada
Prior art keywords
markers
endometrial cancer
endometrial
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3286798A
Other languages
English (en)
Inventor
Garcia Elena Martinez
Ortega Eva Colas
Moreno Antonio Gil
Puigjaner Jaume Reventos
Bruno Domon
Antoine Lesur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacio Institut de Recerca Hospital Universitari Vall dHebron
Original Assignee
Fundacio Institut de Recerca Hospital Universitari Vall dHebron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Institut de Recerca Hospital Universitari Vall dHebron filed Critical Fundacio Institut de Recerca Hospital Universitari Vall dHebron
Publication of CA3286798A1 publication Critical patent/CA3286798A1/en
Pending legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57442Specifically defined cancers of the uterus and endometrial
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/902Oxidoreductases (1.)
    • G01N2333/908Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/948Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486Metalloendopeptidases (3.4.24)
    • G01N2333/96491Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494Matrix metalloproteases, e. g. 3.4.24.7
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3286798A 2016-05-04 2017-03-30 Markers of endometrial cancer Pending CA3286798A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16168328 2016-05-04
CA3022586A CA3022586A1 (en) 2016-05-04 2017-03-30 Markers of endometrial cancer

Publications (1)

Publication Number Publication Date
CA3286798A1 true CA3286798A1 (en) 2025-10-30

Family

ID=56096908

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3286798A Pending CA3286798A1 (en) 2016-05-04 2017-03-30 Markers of endometrial cancer
CA3022586A Pending CA3022586A1 (en) 2016-05-04 2017-03-30 Markers of endometrial cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3022586A Pending CA3022586A1 (en) 2016-05-04 2017-03-30 Markers of endometrial cancer

Country Status (12)

Country Link
US (2) US20190137499A1 (enExample)
EP (3) EP4610655A3 (enExample)
JP (3) JP7240712B2 (enExample)
AU (3) AU2017260806B9 (enExample)
BR (1) BR112018072498A2 (enExample)
CA (2) CA3286798A1 (enExample)
DK (1) DK3452829T3 (enExample)
ES (1) ES2974307T3 (enExample)
FI (1) FI3452829T3 (enExample)
PL (1) PL3452829T3 (enExample)
PT (1) PT3452829T (enExample)
WO (1) WO2017190896A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7421218B2 (ja) * 2017-07-21 2024-01-24 フンダシオ オスピタル ウニベルシタリ バル デブロン-インスティテュート デ レセルカ 子宮内膜癌のマーカとしてのagrin
CN118556133A (zh) 2021-07-23 2024-08-27 瓦尔德西布伦大学医院基金会研究所 子宫内膜癌的生物标记物
CN113493838B (zh) * 2021-09-06 2021-11-23 北京泱深生物信息技术有限公司 子宫内膜癌相关的标志分子及其在诊断子宫内膜癌中的应用
KR102640230B1 (ko) * 2021-09-24 2024-02-22 가천대학교 산학협력단 C-peptide를 처리한 자궁내막 기질세포의 이동성 변화 기작을 이용한 자궁내막 관련질환의 진단 방법 및 자궁내막 관련질환 치료제의 스크리닝 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
AUPO573697A0 (en) * 1997-03-20 1997-04-10 Prince Henry's Institute Of Medical Research Diagnosis of endometrial cancer
US20080226554A1 (en) * 2003-12-23 2008-09-18 Mount Sinai Hospital Methods For Detecting Markers Associated With Endometrial Disease or Phase
WO2008003024A2 (en) * 2006-06-28 2008-01-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Method and composition for diagnosing endometrial cancer
WO2008049239A1 (en) * 2006-10-27 2008-05-02 Mount Sinai Hospital Endometrial biomarkers
CN102549169B (zh) * 2009-07-24 2016-02-24 吉第克生物技术有限公司 子宫内膜癌的标记物

Also Published As

Publication number Publication date
EP4180814A2 (en) 2023-05-17
JP2023040246A (ja) 2023-03-22
AU2017260806B9 (en) 2023-07-20
AU2017260806B2 (en) 2023-06-15
JP7492287B2 (ja) 2024-05-29
PL3452829T3 (pl) 2024-05-20
AU2017260806A1 (en) 2018-12-13
EP3452829B1 (en) 2024-01-24
WO2017190896A1 (en) 2017-11-09
US20190137499A1 (en) 2019-05-09
ES2974307T3 (es) 2024-06-26
EP4610655A2 (en) 2025-09-03
AU2023210591B2 (en) 2025-06-26
JP7240712B2 (ja) 2023-03-16
BR112018072498A2 (pt) 2019-03-12
EP4610655A3 (en) 2025-12-10
EP3452829A1 (en) 2019-03-13
DK3452829T3 (da) 2024-03-25
US20230221323A1 (en) 2023-07-13
CA3022586A1 (en) 2017-11-09
AU2025223935A1 (en) 2025-09-18
JP2019516104A (ja) 2019-06-13
EP4180814A3 (en) 2023-07-12
AU2023210591A1 (en) 2023-08-24
AU2023210591B9 (en) 2025-07-10
FI3452829T3 (fi) 2024-03-20
JP2024116127A (ja) 2024-08-27
PT3452829T (pt) 2024-03-22

Similar Documents

Publication Publication Date Title
IL248601A0 (en) HDL therapeutic markers
IL253160A0 (en) Cancer markers and methods of using them
GB201616912D0 (en) Classification of cancer
ZA201700031B (en) Methylated markers for colorectal cancer
SG11201608347QA (en) Markers for ovarian cancer and the uses thereof
IL261047A (en) Taf1 inhibitors for the therapy of cancer
GB201500584D0 (en) Cancer biomarkers
DK3430162T3 (da) Methyleringsmarkører for pankreascancer
SG10201913528PA (en) Methods of diagnosing cancer
PT3124621T (pt) Marcadores mitocondriais de doenças neurodegenerativas
PT3655778T (pt) Agrin como marcador de cancro do endométrio
GB201602210D0 (en) Detection of cancer
CA3286798A1 (en) Markers of endometrial cancer
GB201620089D0 (en) Photoluminescent markers
EP3415863A4 (en) MARKER
EP3298172A4 (en) Determining risk of prostate cancer recurrence
GB2546773B (en) Cancer
EP3424671A4 (en) MARKER PEN
EP3396307A4 (en) MARKER
GB2549455B (en) Enhanced visibility belisha beacon
EP3184635A4 (en) Cancer marker and cancer determination method
GB201508480D0 (en) Cancer
EP3652541A4 (en) COMBINATION OF MARKERS FOR THE DIAGNOSIS OF CANCER
SG11201702077RA (en) Kit for cancer detection
EP3540367A4 (en) MARKER